56515-89-0

Usage

Uses

Used in Organic Synthesis:
1-Carbethoxyazepan-4-one is used as a synthetic intermediate for the development of a wide range of organic compounds. Its application in this field is due to its unique chemical structure, which allows for further functionalization and the formation of more complex molecules.
Used in Pharmaceutical Industry:
In the pharmaceutical industry, 1-Carbethoxyazepan-4-one is used as a key component in the synthesis of various drugs. Its versatility in organic synthesis enables the development of new therapeutic agents with potential applications in treating different medical conditions.
Used in Chemical Research:
1-Carbethoxyazepan-4-one also finds application in chemical research, where it is employed as a model compound to study various reaction mechanisms and to develop new synthetic methodologies. This contributes to the advancement of chemical knowledge and the discovery of novel chemical processes.

Upstream product

• 105416-56-6 1-aza-5-oxocycloheptane 
• 541-41-3 chloroformic acid ethyl ester 
• 50492-22-3 azepan-4-one hydrochloride 
• 19786-58-4 5-oxoazepane-1,4-dicarboxylic acid diethyl ester 
• 29976-53-2 N-ethoxycarbonyl-4-piperidone 
• 623-73-4 diazoacetic acid ethyl ester 

Downstream Products

• 324784-88-5 4-(4-chlorophenyl)-4-hydroxyazepane-1-carboxylic acid ethyl ester 
• 193542-57-3 4-(4-chlorophenyl)-4-hydroxyhomopiperidine 
• 1621910-36-8 ethyl 4-(benzyloxy)azepane-1-carboxylate 
• 1621910-37-9 C₁₆H₂₃NO₃ 
• 1621910-38-0 C₁₆H₂₃NO₃ 
• 1621910-44-8 (R)-ethyl 4-(tosyloxy)azepane-1-carboxylate 
• 1116680-28-4 C₁₅H₂₁NO₃ 
• 143943-98-0 1-<2-(1-hydroxy-1-phenyl)ethyl>-4-(propananilido)perhydroazepine 
• 143943-96-8 1-<2-(1-hydroxy-1-phenyl)ethyl>-4-anilinoperhydroazepine 
• 143943-97-9 1-<2-(1-propoxy-1-phenyl)ethyl>-4-(propananilido)perhydroazepine 
• 143943-99-1 1-carbethoxy-4-(propananilido)perhydroazepine 
• 143944-00-7 4-(propananilido)perhydroazepine 
• 74134-10-4 (1-Phenethyl-azepan-4-yl)-phenyl-amine 
• 74156-55-1 (1-Allyl-azepan-4-yl)-phenyl-amine 

Relevant academic research and scientific papers

OXIME COMPOUNDS AS AGONISTS OF THE MUSCARINIC M1 AND/OR M4 RECEPTOR

This invention relates to compounds that are agonists of the muscarinic M1 and/or M4 receptor and which are useful in the treatment of diseases mediated by the muscarinic Μ1 and M4 receptors. Also provided are pharmaceutical compositions containing the compounds and the therapeutic uses of the compounds. Compounds provided are of formula (I) where p; q; X1; X2; Y; R1; R2; R3; R4; R5 and R6 are as defined herein.

SUBSTITUTED AZEPINE- AND DIAZEPINE-SULFONAMIDES USEFUL TO INHIBIT 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE-1

In its many embodiments, the present invention relates to a novel class of substituted azepine- and diazepine-sulfonamide compounds useful to inhibit 11BETA-hydroxysteroid dehydrogenase type-1, pharmaceutical compositions containing the compounds, and met

The discovery of azepane sulfonamides as potent 11β-HSD1 inhibitors

Discovery of a series of azepine sulfonamides as potent inhibitors of 11β-hydroxysteroid dehydrogenase type 1 (11β-HSD1) is described. SAR studies at the 4-position of the azepane ring have resulted in the discovery of a very potent compound 30 which has

PYRIMIDINONE DERIVATIVES AND METHODS OF USE THEREOF

The present invention relates to Pyrimidinone Derivatives, compositions comprising a Pyrimidinone Derivative, and methods of using the Pyrimidinone Derivatives for treating or preventing obesity, diabetes, a metabolic disorder, a cardiovascular disease or a disorder related to the activity of G protein-coupled receptor 119 ("GPR119") in a patient.

Design, Synthesis, and Evaluation of Metabolism-Based Analogues of Haloperidol Incapable of Forming MPP+-like Species

The long-term, irreversible, Parkinsonism-like side effects of haloperidol have been speculated to involve several mechanisms. More recently, it has been speculated that the metabolic transformation to MPP+-like species may contribute to the Parkinsonism-like side effects. Because BCPP+ and its reduced analogue have been shown to possess the potential to destroy dopamine receptors in the nigrostriatum, we have designed new analogues of haloperidol lacking the structural features necessary to form neurotoxic quaternary species but retaining their dopamine-binding capacity. The most potent agent at the D2 receptor, the homopiperidine analogue 11, was found to be equipotent to haloperidol. It was also of interest to identify analogues with DA binding profiles similar to that of clozapine at the dopamine receptor subtypes. Evaluation of the proposed agents shows that the ratio of D2 to D4 (2) binding of clozapine was mimicked by 7 [Ki(D2) = 33, Ki(D3) = 200, Ki(D4) = 11 nM; Ki(D2)/Ki(D4) = 3] and 9 [Ki(D2) = 44, Ki(D3) = 170, Ki(D4) = 24 nM; Ki(D2)/Ki(D4) = 2]. A preliminary in-vivo testing of compound 7 shows that its behavioral profile is similar to that of clozapine. This profile suggests that there is a need for further evaluation of these two synthetic agents and their enantiomers for efficacy and lack of catalepsy in animal models.

4-Anilidopiperidine Analgesics. 3. 1-Substituted 4-(Propananilido)perhydroazepines as Ring-Expanded Analogues

A study of ring-expanded analogues of the 4-(propananilido)piperidine analgesics has been undertaken in order to evaluate the influence of this structural modification on both analgesic activity and physical-dependence capacity.Thus, a series of 1-substit